MARY CROWLEY NEWSLETTER: VOLUME 9, ISSUE 4
RUNWAY FOR HOPE: LYNN LENTSCHER’S SPEECH
The Be the Difference Foundation presented Runway for Hope, a luncheon and fashion show benefiting Mary Crowley Cancer Research on September 26th.
MARY CROWLEY NEWSLETTER: VOLUME 9, ISSUE 3
PHASE 1 DOSE ESCALATION STUDY OF MIVEBRESIB IN SOLID TUMORS
First-in-human Study of Mivebresib (ABBV-075), an Oral Pan-inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
BE THE DIFFERENCE FOUNDATION ANNOUNCES RUNWAY FOR HOPE
DALLAS, Texas – Join Be the Difference Foundation for their inaugural luncheon and fashion show, Runway for Hope, benefitting Mary Crowley Cancer Research,
MARY CROWLEY NEWSLETTER: VOLUME 9 ISSUE 2
MARY CROWLEY NEWSLETTER: VOLUME 9 ISSUE 1
TEMPUS AND MARY CROWLEY JOIN FORCES TO TAKE ON LUNG CANCER
Tempus is a Chicago-based leading technology company that is ushering precision medicine as a means to advance cancer care.
PHASE IIIB SAFETY RESULTS FROM AN EXPANDED ACCESS PROTOCOL OF TALIMOGENE LAHERPAREPVEC FOR PATIENT WITH UNRESECTED, STAGE IIIB-IVM1C MELANOMA.
Phase IIIb safety results from an expanded access protocol of talimogene laherparepvec for patient with unresected, stage IIIB-IVM1c melanoma.